Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment

Hypoxia induces Hif-1α and selects for loss of wild-type p53 function, both of which can promote tumor cell survival. We evaluated the ability of TRAIL to induce apoptosis of human tumor cell lines exposed to hypoxia. H460 lung cancer cells express low levels of Hif-1α, stabilize wild-type p53 during hypoxia, and undergo TRAIL-induced apoptosis. In U2OS osteosarcoma or PA1 ovarian teratocarcinoma cells, high levels of Hif-1α and low levels of stable p53 are detected during hypoxia, and cells undergo low levels of TRAIL-induced apoptosis as compared to H460 cells. H460 cells are sensitized to TRAIL-induced apoptosis, whereas U2OS are protected, and little apoptosis is observed in relatively TRAIL-resistant PA1 during hypoxia. Forced expression of Hif-1α is also surprisingly a potent inducer of apoptosis in wild-type p53 expressing H460 cells and further promotes TRAIL-induced apoptosis. TRAIL-sensitive wild-type p53-expressing HCT116 colon carcinoma cells modestly elevate Hif-1α levels and are equally or slightly more sensitive to TRAIL during hypoxia. In contrast, p53-null HCT116 have higher levels of Hif-1α during normoxia and are extremely sensitive to TRAIL, but are protected from TRAIL-induced apoptosis during hypoxia. We hypothesize that a hypoxic tumor microenvironment may alter sensitivity to TRAIL, which may be impacted by Hif-1α levels and p53 status. These findings suggest that particular attention to hypoxic regions of tumors and sensitizers to hypoxia-induced cell death may be required to optimize therapeutic combinations using TRAIL.

[1]  P. V. van Diest,et al.  HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor , 2005, BMC Cancer.

[2]  Amato J Giaccia,et al.  The role of p53 in hypoxia-induced apoptosis. , 2005, Biochemical and biophysical research communications.

[3]  K. Nakanishi,et al.  Expression of Hypoxia-Inducible Factor-1α Protein Predicts Survival in Patients with Transitional Cell Carcinoma of the Upper Urinary Tract , 2005, Clinical Cancer Research.

[4]  P. Vaupel,et al.  Hypoxia and anemia: effects on tumor biology and treatment resistance. , 2005, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[5]  T. Burns,et al.  Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. , 2004, Cancer cell.

[6]  Clemencia Pinilla,et al.  Cellular, Biochemical, and Genetic Analysis of Mechanism of Small Molecule IAP Inhibitors* , 2004, Journal of Biological Chemistry.

[7]  W. El-Deiry,et al.  Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity , 2004, Molecular and Cellular Biology.

[8]  A. Ashkenazi,et al.  Targeting death receptors in cancer with Apo2L/TRAIL. , 2004, Current opinion in pharmacology.

[9]  Moonil Kim,et al.  Hypoxia Inhibits Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Blocking Bax Translocation , 2004, Cancer Research.

[10]  J. Brown,et al.  Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.

[11]  A. Rustgi,et al.  Targeting Bcl-xL in esophageal squamous cancer to sensitize to chemotherapy plus TRAIL-induced apoptosis while normal epithelial cells are protected by blockade of caspase 9 , 2004, Cell Death and Differentiation.

[12]  C. Belka,et al.  Influence of hypoxia on TRAIL-induced apoptosis in tumor cells. , 2004, International journal of radiation oncology, biology, physics.

[13]  P. Maxwell,et al.  HIF-1, An Oxygen and Metal Responsive Transcription Factor , 2004, Cancer biology & therapy.

[14]  Clemencia Pinilla,et al.  Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. , 2004, Cancer cell.

[15]  Wafik S El-Deiry,et al.  TRAIL and apoptosis induction by TNF-family death receptors , 2003, Oncogene.

[16]  A. Giaccia,et al.  HIF-1 as a target for drug development , 2003, Nature Reviews Drug Discovery.

[17]  G. Semenza Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[18]  W. El-Deiry,et al.  Flow cytometric analysis of tumor suppressor gene-induced apoptosis. , 2003, Methods in molecular biology.

[19]  K. Peters,et al.  Tirapazamine: a hypoxia-activated topoisomerase II poison. , 2002, Cancer research.

[20]  D. Seol,et al.  Hypoxia inhibition of apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). , 2002, Biochemical and biophysical research communications.

[21]  Yahong Lin,et al.  TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. , 2002, Genes & development.

[22]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[23]  W. el-Deiry,et al.  Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling , 2001, Cell Death and Differentiation.

[24]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[25]  D. Dicker,et al.  Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. , 2001, International journal of oncology.

[26]  Michael T. Fisher,et al.  Molecular determinants of response to TRAIL in killing of normal and cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.